Synonym
Tulmimetostat; Tulmimetostatum; CPI-0209
IUPAC/Chemical Name
(R)-7-chloro-2-((1r,4R)-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
InChi Key
CAAWBLRXQXMGHV-JAGNJQOISA-N
InChi Code
InChI=1S/C28H36ClN3O5S/c1-15-10-23(38-5)21(27(34)31-15)12-30-26(33)20-11-22(29)25-24(16(20)2)36-28(3,37-25)17-6-8-18(9-7-17)32-13-19(14-32)35-4/h10-11,17-19H,6-9,12-14H2,1-5H3,(H,30,33)(H,31,34)/t17-,18-,28-/m1/s1
SMILES Code
O=C(C1=CC(Cl)=C(O[C@](C)([C@H]2CC[C@H](N3CC(OC)C3)CC2)O4)C4=C1C)NCC5=C(SC)C=C(C)NC5=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
562.12
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Keller PJ, Adams EJ, Wu R, Côté A, Arora S, Cantone N, Meyer R, Mertz JA,
Gehling V, Cui J, Stuckey JI, Khanna A, Zhao F, Chen Z, Yu Z, Cummings RT, Taimi
M, Lakhani NJ, Rasco D, Gutierrez M, Duska L, Devitt M, Rippley R, Levell J,
Truong J, Wang J, Sun K, Trojer P. Comprehensive Target Engagement by the EZH2
Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer
Res. 2024 Aug 1;84(15):2501-2517. doi: 10.1158/0008-5472.CAN-24-0398. PMID:
38833522; PMCID: PMC11292196.
2: Goleij P, Heidari MM, Tabari MAK, Hadipour M, Rezaee A, Javan A, Sanaye PM,
Larsen DS, Daglia M, Khan H. Polycomb repressive complex 2 (PRC2) pathway's role
in cancer cell plasticity and drug resistance. Funct Integr Genomics. 2025 Mar
6;25(1):53. doi: 10.1007/s10142-025-01563-8. PMID: 40048009.
